As an antiapoptotic protein, MCL-1 has become an attractive target and is implicated with venetoclax resistance in hematologic malignancies [7], motivating us to investigate AZD5991 alone and in combination with venetoclax in our resistant MCL models. This evidence concerns the gene MCL1 and mantle cell lymphoma.